Health ❯ Pharmaceuticals ❯ Drug Development

Obesity Treatments

Clinical Trials Danuglipron GLP-1 Drugs Mounjaro CagriSema Market Trends

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal